inventor
submit
award
patent
describ
supramolecular
polypeptid
biomateri
healthcar
use
find
util
biomed
applic
rang
immunomodul
drug
deliveri
tissu
regener
defect
repair
cell
deliveri
combin
thereof
mani
selfassembl
system
investig
preclin
research
among
rel
success
translat
approv
devic
therapeut
current
clinic
use
tend
possess
follow
featur
enabl
success
chemic
definitionhighli
specifi
control
materi
composit
assembl
properti
bioactiv
contrast
biolog
sourc
materi
manufacturabilityth
extent
platform
manufactur
rel
eas
minimum
cost
maximum
reproduc
tunabilityth
abil
adjust
amount
multipl
select
activ
compon
materi
precis
reproduc
synthet
supramolecular
system
tend
featur
properti
well
beyond
natur
deriv
materi
select
platform
discuss
base
featur
meaning
translat
clinic
practic
steadi
progress
toward
clinic
translat
includ
spheric
assembl
viruslik
particl
design
protein
nanoparticl
peptid
amphiphil
figur
elong
structur
nanofib
fiberform
peptid
amphiphil
filament
phage
figur
timelin
develop
shown
figur
first
engin
supramolecular
structur
translat
effect
viruslik
particl
vlp
multiprotein
construct
selfassembl
mimic
organ
structur
immunogen
nativ
virus
lack
infecti
genet
materi
figur
develop
preced
supramolecular
materi
discuss
see
timelin
figur
vlp
potent
immunogen
abl
stimul
b
cellantibodi
respons
tcell
respons
cytotox
tcell
respons
owe
lack
viral
genom
vlpbase
vaccin
circumv
risk
associ
supramolecular
materi
compos
protein
peptid
receiv
consider
attent
toward
rang
diseas
condit
vaccin
drug
deliveri
owe
rel
new
class
materi
bulk
work
date
preclin
howev
exampl
approv
treatment
particularli
vaccin
dentistri
hemostasi
demonstr
translat
potenti
supramolecular
polypeptid
critic
mileston
clinic
develop
class
materi
current
approv
supramolecular
polypeptid
therapi
describ
studi
addit
exampl
notyetapprov
materi
steadili
advanc
toward
clinic
use
also
featur
spheric
assembl
viruslik
particl
design
protein
nanoparticl
spheric
peptid
amphiphil
highlight
follow
fiberform
system
fibril
peptid
fiberform
peptideamphiphil
filament
bacteriophag
past
decad
research
built
expans
toolbox
selfassembl
peptid
protein
offer
uniqu
advantag
tradit
small
molecul
polym
rang
biomed
applic
first
exampl
synthet
selfassembl
bioinspir
deriv
nativ
protein
increas
familiar
design
rule
govern
supramolecular
assembl
recent
facilit
de
novo
design
class
materi
abil
creat
predict
engineer
supramolecular
structur
led
implement
sever
materi
within
biomed
applic
review
highlight
selfassembl
polypeptid
materi
clinic
translat
also
discuss
advantag
properti
featur
enabl
clinic
implement
recent
review
preclin
work
relat
class
materi
includ
selfassembl
immunomodul
materi
selfassembl
materi
cell
deliveri
selfassembl
biomateri
whole
reader
refer
review
articl
indic
properli
design
polypeptid
selfassembl
rang
predict
structur
includ
nanofib
micel
nanoparticl
extend
network
architectur
attenu
inactiv
live
virus
highlight
advantag
supramolecular
system
composit
defin
analog
biolog
structur
virus
also
advantag
subunit
vaccin
base
viral
protein
peptid
conjug
carrier
protein
commonli
requir
higher
frequent
dose
adjuv
effect
inactiv
attenu
virus
altern
previou
platform
vlp
develop
display
array
epitop
mimic
surfac
nativ
virus
effect
subunit
peptid
vaccin
thu
improv
immunogen
properti
vlp
like
virus
come
rang
structur
includ
singl
capsid
protein
multipl
capsid
protein
without
lipid
envelop
vlp
consist
multipl
capsid
protein
express
assembl
via
subsequ
process
coexpress
polycistron
gene
within
cell
sever
addit
aspect
vlp
contribut
clinic
translat
wherea
first
translat
vlpbase
vaccin
rais
antibodi
natur
occur
viru
capsid
protein
assembl
structur
vlp
also
use
vehicl
display
heterolog
antigen
associ
infecti
diseas
modular
platform
describ
copyright
asbmb
right
adapt
permiss
copyright
elsevi
b
adapt
permiss
copyright
elsevi
c
adapt
permiss
becom
increasingli
complex
becom
increasingli
challeng
manufactur
larg
scale
multisubunit
chimer
type
vlp
must
overcom
challeng
fortun
larg
assort
express
system
bacteri
yeast
insect
plant
mammalian
cellfre
develop
product
new
vlp
platform
candid
idea
use
noninfecti
viru
particl
develop
prophylact
human
vaccin
first
becam
attract
noninfecti
vlp
compos
surfac
antigen
hepat
b
viru
hbsag
also
known
australia
antigen
discov
human
sera
first
vlpbase
human
vaccin
consist
hbsag
vlp
deriv
human
plasma
licens
unit
state
figur
subsequ
advent
hivaid
render
plasmaderiv
product
challeng
hbsag
particl
produc
recombinantli
yeast
first
recombin
human
vaccin
recombivax
hb
licens
merck
three
year
later
engerixb
similar
hbv
vaccin
licens
glaxosmithklin
took
anoth
year
next
recombin
vlpbase
vaccin
licens
human
use
gardasil
licens
merck
vaccin
hpv
protect
hpvrelat
diseas
cervic
cancer
sever
laboratori
concurr
observ
recombinantli
express
hpv
viru
capsid
protein
selfassembl
vlp
resembl
nativ
virion
structur
earli
base
observ
merck
research
laboratori
mrl
initi
hpv
vaccin
program
time
grow
number
hpv
genotyp
identifi
associ
benign
genit
wart
precursor
lesion
cervic
cancer
mrl
devis
strategi
produc
quadrival
hpv
vlp
would
protect
cervic
cancer
caus
well
genit
wart
caus
hpv
sever
concurr
studi
addit
critic
success
hpv
vaccin
one
import
advanc
develop
vitro
method
produc
hpv
virion
hpv
lifecycl
link
human
epitheli
tissu
differenti
difficult
achiev
vitro
kreider
et
al
overcam
challeng
overcom
develop
complex
xenograft
model
human
foreskin
epitheli
tissu
infect
hpv
grown
renal
capsul
athym
mice
method
allow
product
infecti
hpv
anim
challeng
studi
publish
continu
advanc
hpv
vaccin
two
studi
demonstr
measur
serum
antibodi
respons
vlp
immun
subsequ
protect
later
challeng
third
demonstr
import
maintain
nativ
vlp
structur
optim
vaccin
efficaci
anoth
key
contribut
success
mrl
hpv
vaccin
came
work
develop
manufactur
process
hbsag
product
saccharomyc
cerevisia
provid
foundat
develop
method
design
express
purifi
larg
amount
hpv
vlp
hpv
vlp
evalu
first
time
human
monoval
vaccin
phase
clinic
trial
demonstr
safeti
immunogen
monoval
vaccin
chosen
owe
avail
robust
model
evalu
immunogen
model
three
hpv
type
yet
develop
phase
studi
outcom
promis
report
signific
advers
effect
second
studi
test
abil
monoval
hpv
vlp
efficaci
prevent
hpv
infect
provid
first
demonstr
vaccin
hpv
vlp
could
prevent
diseas
favor
result
support
develop
multival
vaccin
spur
advanc
program
impress
efficaci
data
accept
safeti
profil
first
hpv
vlp
vaccin
gardasil
licens
see
timelin
figur
anoth
hpv
vlp
human
vaccin
prevent
cervic
cancer
cervarix
develop
glaxosmithklin
licens
unit
state
vaccin
includ
hpv
type
produc
use
insect
cell
infect
recombin
baculoviru
cervarix
demonstr
efficaci
cervic
intraepitheli
neoplasia
lesion
contain
hpv
indic
crossprotect
hpv
type
lead
protect
cervic
cancer
hecolin
xiamen
innovax
biotech
recombin
vlpbase
vaccin
prophylact
copyright
aaa
right
adapt
permiss
copyright
nation
academi
scienc
b
left
adapt
permiss
copyright
american
chemic
societi
b
right
adapt
permiss
c
left
adapt
permiss
copyright
elsevi
c
right
adapt
permiss
use
hepat
e
viru
infect
licens
china
past
decad
vlp
vaccin
play
critic
role
improv
human
health
continu
appli
new
diseas
vlpbase
vaccin
current
clinic
trial
treatment
mani
infecti
diseas
hbv
hiv
hpv
human
parvoviru
influenza
viru
norwalk
viru
ebola
viru
sever
acut
respiratori
syndromerel
coronaviru
inclus
preclin
test
list
broaden
even
diseas
includ
chikungunya
viru
west
nile
viru
mump
viru
mention
introduct
one
key
strateg
strength
supramolecular
system
modular
tend
possess
vlp
modular
exemplifi
chimer
vlp
epitop
choic
variou
diseas
insert
particleform
protein
provid
new
epitop
insert
way
disrupt
selfassembl
present
epitop
surfac
particl
antigen
immunogen
modular
system
maintain
abl
insert
epitop
choic
rang
therapeut
applic
becom
quit
broad
exampl
sever
clinic
studi
current
evalu
chimer
vlp
vaccin
treatment
noninfecti
diseas
cancer
melanoma
neurodegen
diseas
alzheim
diseas
autoimmun
diseas
allerg
rhinoconjunct
asthma
disord
anoth
approach
includ
chosen
epitop
antigen
separ
express
vlp
target
protein
conjug
togeth
approach
often
prefer
necessari
due
differ
optim
express
condit
compon
thu
postproduct
method
develop
link
vlp
target
antigen
achiev
genet
manipul
coupl
via
supramolecular
coval
bond
encapsul
cargo
disassembl
reassembl
purifi
vlp
presenc
desir
molecul
coupl
chemistri
rang
use
bifunct
crosslink
click
chemistri
sortasemedi
attach
polyhistidinentani
affinitytag
interact
conjug
vlp
target
antigen
notabl
postproductionmodifi
vlp
led
sever
platform
current
test
clinic
trial
although
rang
chemic
crosslink
strategi
develop
vlp
conjug
target
antigen
multipl
reactiv
site
lead
heterogen
coupl
unfavor
epitop
display
bachmann
group
address
challeng
use
spytagspycatch
system
spytag
peptid
form
spontan
irrevers
isopeptid
bond
spycatch
protein
partner
spycatchervlp
platform
express
escherichia
coli
mix
spytagantigen
form
pluganddisplay
decor
vlp
anoth
highli
modular
tunabl
approach
allow
incorpor
wide
varieti
antigen
vlp
surfac
group
report
spycatchervlp
decor
cidr
antigen
gener
robust
antibodi
respons
singl
immun
without
requir
adjuv
platform
show
promis
applic
drug
deliveri
enzym
scaffold
biosensor
cancer
immunotherapi
mitig
need
complex
chimer
protein
express
incorpor
unnatur
amino
acid
would
necessari
coppercatalyz
azidealkyn
cycloaddit
click
chemistri
chemoselect
bioconjug
reaction
vlp
owe
structur
definit
flexibl
formul
also
make
use
experiment
tool
studi
basic
aspect
immun
usual
rang
diamet
nm
optim
size
drainag
lymph
node
subsequ
interact
b
cell
wherea
differenti
b
cell
memori
b
cell
extens
studi
cellular
molecular
level
fate
memori
b
cell
upon
antigen
reencount
compar
less
wellstudi
bachmann
group
use
vlp
model
system
abl
track
vlpspecif
b
cell
via
flow
cytometri
histolog
follow
memori
b
cell
respons
unexpectedli
found
secondari
b
cell
respons
secondari
plasma
cell
gener
wherea
b
cell
recruit
parallel
primari
b
cell
respons
phenomenon
allow
plastic
memori
b
cell
repertoir
upon
multipl
antigen
exposur
shortcom
vlp
includ
requir
continu
wellregul
cold
chain
neg
impact
distribut
develop
world
address
challeng
chackerian
group
develop
vlpbase
vaccin
candid
compat
spray
dri
thu
enhanc
stabil
broad
rang
temperatur
platform
target
highli
conserv
broadli
neutral
epitop
hpv
minor
capsid
protein
vaccin
elicit
hightit
longlast
antibodi
immun
respons
spray
dri
vlp
highli
immunogen
mous
model
store
month
either
room
temperatur
constraint
vlp
subject
includ
rel
small
size
epitop
accommod
within
particl
exampl
larg
antigen
hiv
envelop
influenza
hemagglutinin
protein
larg
packag
within
nativ
vlp
practic
vlp
platform
also
limit
manufactur
consider
exampl
vlp
deriv
e
coli
wide
use
effici
express
system
biotechnolog
industri
high
degre
heterogen
physic
properti
includ
shape
diamet
particl
particl
requir
postpurif
disassembl
reassembl
optim
condit
addit
may
possibl
produc
highli
immunogen
vlp
prepar
antigen
might
viabl
vlp
context
stabl
formul
develop
formul
must
resist
aggreg
upon
exposur
low
salt
protein
concentr
well
protect
surfac
adsorpt
aggreg
result
heat
stress
physic
agit
order
achiev
multipleyear
stabil
requir
market
vaccin
newer
express
system
conjunct
innov
purif
strategi
could
determin
pace
next
gener
vlpbase
vaccin
candid
exampl
yeast
insect
mammalian
express
system
use
circumv
limit
bacteri
express
suboptim
ph
lipid
composit
within
bacteria
addit
advanc
highthroughput
biophys
structur
analys
recombin
vlp
may
play
key
role
assess
vlp
candid
electron
microscopi
electrospray
differenti
mobil
analysi
atom
forc
microscopi
xray
crystallographi
dynam
light
scatter
provid
quantit
structur
data
vaccin
candid
play
valuabl
role
ensur
product
robust
earli
clinic
develop
stage
beyond
altern
particl
inspir
natur
viru
capsid
protein
fulli
design
protein
nanoparticl
receiv
consider
interest
although
bottomup
approach
design
nanomateri
popular
year
ago
develop
supramolecular
polypeptid
materi
success
medic
technolog
initi
slow
hinder
sheer
divers
possibl
selfassembl
structur
lack
design
rule
yeat
group
develop
approach
base
molecular
symmetri
fabric
protein
assembl
rang
predict
architectur
strategi
breakthrough
ration
selfassembl
protein
design
past
year
capac
model
predict
protein
structur
energet
increas
along
comput
power
lead
comput
design
de
novo
selfassembl
protein
nanoparticl
baker
group
use
natur
occur
oligomer
protein
build
block
design
cagelik
assembl
accuraci
recent
gener
hyperst
protein
icosahedron
via
symmetr
model
coupl
comput
proteinprotein
interfac
design
structur
robust
genet
fusion
make
notabl
modular
platform
could
use
multival
epitop
display
well
drug
deliveri
take
inspir
natur
also
proven
invalu
design
mechan
chemic
stabl
nanoparticl
raman
et
al
design
selfassembl
nanoparticl
base
viru
capsid
via
superposit
differ
protein
oligomer
domain
onto
symmetri
axe
icosahedron
shown
figur
monom
build
block
consist
protein
chain
made
two
coil
coil
connect
short
linker
region
associ
coil
coil
caus
assembl
monom
roughli
spheric
nanoparticl
selfassembl
protein
nanoparticl
versatil
flexibl
design
allow
optim
biophys
immunolog
properti
make
desir
vaccin
platform
wherea
synthet
peptid
usual
suffici
immunogen
requir
adjuv
burkhard
group
develop
selfassembl
protein
nanoparticl
platform
display
b
cell
epitop
produc
vaccin
selfadjuv
qualiti
platform
current
develop
improv
malaria
vaccin
rt
base
circumsporozoit
protein
plasmodium
falciparum
selfassembl
protein
nanoparticl
abl
stimul
high
titer
high
avid
antibodi
present
tcell
eptiop
stimul
produc
longterm
memori
tcell
mous
model
vaccin
candid
base
platform
current
undergo
phase
clinic
trial
princip
advantag
design
protein
nanoparticl
chemic
definit
abil
use
comput
method
design
nanoparticl
differ
geometri
size
open
door
applic
drug
deliveri
shape
size
deliveri
vehicl
crucial
howev
manufactur
platform
similar
vlp
challeng
due
multisubunit
natur
need
recombinantli
express
micellar
nanocarri
compos
amphiphil
molecul
particular
success
pharmaceut
realm
tool
increas
bioavail
retent
solubl
variou
drug
howev
review
shall
focus
peptid
amphiphil
pa
relat
theme
clinic
translat
peptidebas
materi
structur
selfassembl
molecul
compos
hydrophob
domain
usual
alkyl
chain
hydrophil
peptid
domain
pa
assembl
driven
hydrophobichydrophob
interact
water
bioactiv
program
hydrophil
peptid
head
group
see
figur
comprehens
review
pa
use
biomed
applic
reader
direct
acar
et
al
target
diagnost
theranost
platform
deriv
peptid
amphiphil
micel
pam
increas
size
hydrophob
head
group
push
system
toward
micellar
pack
morpholog
micel
consist
biolog
activ
peptid
attach
hydrophob
alkyl
tail
via
bulki
polyethylen
glycol
peg
spacer
peg
spacer
allow
enhanc
blood
circul
time
retain
pack
paramet
necessari
micel
format
molecul
shown
circul
blood
stream
without
caus
blockag
clear
via
reticuloendotheli
system
renal
system
clearanc
toxic
pam
current
preclin
develop
cancer
atherosclerosi
diagnost
applic
cancer
applic
fluorescentlylabel
pa
fibrinbind
peptid
creka
use
target
glioblastoma
cell
upon
intraven
administr
gliomabear
mice
nontarget
micel
passiv
accumul
fibrin
deposit
characterist
tumor
vasculatur
micel
display
enhanc
tumor
home
earli
h
administr
without
induc
cytotox
tissu
damag
toward
therapi
atherosclerosi
creka
target
peptid
antithrombin
peptid
call
hirulog
fluoresc
molecul
assembl
theranost
micel
fibrintarget
micel
could
also
function
addit
gadolinium
chelat
diethylenetriaminepentaacet
acid
allow
plaqu
local
visual
use
magnet
reson
imag
mri
imag
similar
pam
design
target
monocyt
strategi
diagnos
atherosclerosi
via
area
heighten
immunolog
activ
character
diseas
similarli
previous
describ
vaccin
nanoparticl
pa
micel
abl
elicit
either
humor
cellmedi
immun
without
addit
adjuv
antigen
simpli
conjug
tail
domain
molecul
prior
selfassembl
black
et
al
abl
assembl
cylindr
micel
monom
consist
dialkyl
tail
conjug
peptid
contain
known
cytotox
tcell
epitop
model
tumor
antigen
ovalbumin
dic
ova
micel
abl
stimul
ovaspecif
tcell
offer
vivo
protect
tumor
without
addit
adjuv
observ
spur
addit
immunolog
studi
expand
upon
potenti
peptid
amphiphil
micel
vaccin
platform
barrett
et
al
use
group
streptococcu
ga
bcell
antigen
coupl
dic
tail
drove
selfassembl
cylindr
micel
induc
micellemedi
immun
respons
without
adjuv
stronger
seen
convent
goldstandard
vaccin
formul
although
spheric
assembl
peptid
amphiphil
yet
reach
regulatori
approv
clinic
applic
versatil
modular
demonstr
success
preclin
work
encourag
clinic
translat
supramolecular
materi
limit
spheric
morpholog
extend
structur
high
aspect
ratio
also
seen
consider
develop
toward
varieti
medic
technolog
figur
promin
among
fibrillar
assembl
peptid
deriv
structur
investig
past
year
made
progress
toward
therapi
hemostasi
dentistri
wound
heal
immunolog
studi
structur
biolog
alexand
rich
research
group
zhang
discov
selfassembl
peptid
base
dnabind
protein
zuotin
peptid
form
amphiphil
tape
two
distinct
surfac
one
hydrophob
hydrophil
also
contain
complementari
charg
residu
addit
favor
fold
see
figur
follow
discoveri
mimic
nativ
peptid
design
mutat
charg
hydrophob
residu
leav
pattern
intact
mimic
demonstr
selfassembl
peptid
motif
sequencespecif
anomali
could
recreat
similar
system
form
first
step
toward
design
rule
fibril
peptid
design
peptid
shown
also
form
macroscop
membran
support
attach
mammalian
cell
demonstr
util
biomateri
subsequ
found
origin
synthet
sequenc
raradada
modifi
form
rada
spontan
form
hydrogel
entangl
nanofib
saltcontain
solut
cell
cultur
media
mixtur
peptid
bear
multipl
bioactiv
group
could
incorpor
singl
macroscop
gel
dose
variou
amount
monomer
peptid
gel
mixtur
addit
incorpor
ligand
epitop
within
materi
simpli
requir
extens
peptid
either
terminu
desir
sequenc
thu
lower
barrier
synthet
difficulti
biolog
research
gel
subsequ
develop
toward
neuron
regener
cytokin
deliveri
biotinyl
scaffold
versatil
protein
deliveri
applic
releas
protein
small
molecul
rada
hydrogel
larg
depend
size
protein
cargo
regardless
charg
hydrophil
charact
allow
wide
varieti
biomolecul
deliv
gel
besid
physic
entrap
biotinsandwich
approach
use
tether
insulinlik
growth
factor
gel
long
term
local
bioactiv
scaffold
biotinyl
provid
advantag
modular
within
hydrogel
deliveri
system
biotinyl
protein
immobil
biotinyl
fiber
via
streptavidin
linkag
biotinyl
fiber
investig
myocardi
regener
follow
infarct
show
success
rat
inject
infarct
heart
along
cardiac
progenitor
cell
although
rada
nanofib
investig
preclin
wide
rang
medic
applic
clinic
success
hemostat
agent
market
trade
name
purastat
matrix
ltd
product
compos
sole
peptid
dissolv
steril
water
form
fiber
contact
biolog
fluid
selfassembl
provid
physic
blockag
order
limit
bleed
site
applic
although
peptid
use
hemostat
still
activ
develop
compon
layerbylay
wound
dress
origin
peptid
use
surgic
hemostat
multipl
surgeri
dens
mesh
creat
neutral
ph
peptid
becam
purastat
first
test
hemostat
agent
demonstr
hemostasi
rat
stop
bleed
appli
aqueou
solut
wound
skin
brain
spinal
cord
femor
arteri
liver
rapid
induct
hemostasi
circumv
need
compon
clot
cascad
activ
hemostat
avoid
use
heat
pyrogen
substanc
effect
presenc
anticoagul
therapi
without
caus
pronounc
tissu
respons
although
peptid
slightli
acid
caus
signific
inflamm
anim
clinic
studi
even
appli
brain
also
name
peptid
first
test
hemostat
human
surgeri
japan
cardiovascular
procedur
later
endoscop
mucos
resect
treatmentrel
advers
event
either
trial
purastat
limit
rel
low
pressur
hemorrhag
comparison
major
arteri
injuri
gener
util
versatil
biodegrad
hemostat
clinic
trial
monitor
postmarket
perform
purastat
vascular
surgeri
test
use
purastat
endoscop
submucos
dissect
schedul
begin
soon
purastat
alreadi
achiev
ce
mark
europ
current
receiv
medic
devic
product
registr
approv
number
countri
includ
thailand
mexico
indonesia
australia
initi
studi
rada
famili
peptid
inspir
develop
gener
design
principl
form
nanofib
peptid
shown
similar
selfassembl
properti
notabl
peptid
p
develop
agg
et
al
would
eventu
lead
develop
enamel
regener
product
curodont
first
sequenc
design
agg
et
al
mimic
transmembran
protein
peptid
design
de
novo
base
pattern
found
transmembran
protein
shown
form
high
aspectratio
fibril
tangl
form
hydrogel
independ
ph
manner
similar
proteininspir
peptid
base
current
peptid
market
european
union
eu
switzerland
form
treatment
dental
enamel
cari
function
creat
local
environ
enhanc
enamel
miner
upon
inject
monomer
peptid
assembl
nanotap
creat
matrix
respect
resembl
matrix
environ
necessari
enamel
deposit
major
design
improv
preced
final
curodont
peptid
sequenc
introduct
phsensit
agg
et
al
ration
modifi
origin
peptid
sequenc
neg
charg
ph
thu
creat
electrostat
repuls
allow
peptid
remain
monomer
unassembl
state
upon
switch
acid
ph
howev
acid
residu
becam
proton
monom
assembl
tape
phsensit
allow
situ
assembl
peptid
nanofib
hypothes
improv
efficaci
curodont
materi
abl
complet
fill
deminer
defect
vari
shape
size
phsensit
assembl
specif
explor
context
enamel
reminer
simul
intraor
condit
employ
assess
perform
selfassembl
scaffold
administ
basic
solut
allow
fibrili
incub
cyclic
ph
studi
complet
enamel
lesion
form
extract
human
teeth
indic
p
scaffold
caus
hydroxyapatit
miner
peptid
solut
appli
thu
posit
signific
result
obtain
without
need
special
applic
method
poorli
translat
anim
model
signific
advantag
develop
polypeptid
biomateri
toward
dental
applic
enamel
restor
properti
p
develop
preclin
model
credenti
found
curodont
launch
compani
first
product
safeti
efficaci
verifi
clinic
trial
treat
dental
cari
receiv
market
approv
celabel
medic
devic
eu
keep
origin
peptid
design
final
formul
curodont
compos
monomer
acid
peptid
p
dissolv
water
addit
bioactiv
agent
follow
singl
applic
size
color
lesion
significantli
improv
observ
one
month
treatment
peptid
nanofib
also
increasingli
receiv
attent
immunolog
context
area
group
activ
howev
focu
clinic
develop
materi
yet
reach
clinic
trial
applic
briefli
describ
reader
refer
recent
review
expans
descript
burgeon
field
discoveri
fibril
peptid
rais
strong
antibodi
respons
without
requir
supplement
adjuv
materi
investig
preclin
toward
rang
diseas
condit
includ
malaria
staphylococu
aureu
infect
influenza
west
nile
viru
cancer
cocain
abus
immunogen
peptid
nanofib
produc
coassembl
fibril
peptid
extend
specif
epitop
hapten
along
fibril
peptid
bear
tcell
epitop
stimul
antibodybcel
respons
tcell
respons
tcell
respons
rais
tunabl
magnitud
without
caus
inflamm
recent
extens
fibril
peptid
technolog
includ
assembl
contain
peptid
therapeut
activ
compound
drugpeptid
formul
hydrophob
electrostat
interact
induc
assembl
molecul
fibrillar
network
much
way
pure
peptid
system
recent
describ
exampl
strategi
us
food
drug
administr
fda
approv
anticanc
drug
pemetrex
conjug
fouramino
acid
peptid
use
mri
contrast
agent
form
drug
depot
near
tumor
site
dual
function
materi
contrast
depot
format
possibl
peptidedrug
conjug
form
fibrillar
hydrogel
high
concentr
form
drug
depot
lower
concentr
circul
act
mri
contrast
agent
rang
strategi
likewis
employ
fibril
peptid
alter
deliveri
pharmacokinet
variou
drug
exampl
hartgerink
cowork
show
sever
differ
multival
drug
molecul
clodron
heparin
suramin
could
use
stabil
fibrillar
hydrogel
shield
surfac
charg
peptid
would
otherwis
inhibit
gelat
thu
form
drug
depot
naphthalenemodifi
peptid
explor
carri
hydrophob
drug
curcumin
requir
carrier
transport
due
low
solubl
exampl
highlight
consider
futur
potenti
peptid
nanofib
toward
clinic
applic
alongsid
use
peptid
peptid
amphiphil
compos
peptid
head
group
alkyl
tail
relat
class
materi
seen
consider
interest
creat
supramolecular
nanofib
see
figur
although
selfassembl
peptid
amphiphil
spheric
structur
known
time
landmark
paper
hartgerink
stupp
colleagu
catalyz
much
interest
abil
class
molecul
form
nanofibr
materi
specif
biomed
applic
report
nanofib
spontan
assembl
peptid
amphiphil
parallel
bundl
promot
miner
hydroxyapatit
sinc
fibrillar
peptid
amphiphil
materi
explor
broad
rang
medic
applic
rang
wound
heal
bone
heal
deliveri
protein
nervou
tissu
repair
other
addit
chemistri
develop
stabil
materi
exampl
toward
applic
mechan
integr
necessari
adhes
group
incorpor
hydrophil
head
render
fibrou
gel
selfheal
strain
mechan
recent
exampl
clinic
direct
peptid
amphiphil
nanofib
use
deliv
bioactiv
protein
bone
morphogen
protein
bmp
induc
osteogenesi
environ
mimick
nativ
bone
growth
exampl
includ
nerv
repair
benefit
bioactiv
parallel
align
fibrou
scaffold
burn
injuri
heparinmimet
gel
induc
format
vascular
collagenrich
tissu
peptid
amphiphil
also
use
deliv
bioactiv
cargo
outsid
regen
context
includ
electrostat
complex
antisens
oligonucleotid
cation
peptid
head
form
depot
sustain
releas
oligonucleotid
network
peptidebas
fiber
morpholog
similar
extracellular
matrix
also
highli
use
vitro
cultur
materi
util
cell
deliveri
vehicl
demonstr
transplant
islet
cell
bone
marrowderiv
proangiogen
cell
cultur
prior
transplant
although
work
fibrou
peptid
amphiphil
remain
larg
preclin
date
anticip
come
year
see
mani
applic
brought
forward
approv
therapeut
filament
bacteriophag
see
figur
repres
addit
step
progress
nanofiberform
biomateri
although
product
consider
differ
chemic
synthesi
pa
short
peptid
elong
morpholog
polyamino
acid
composit
similar
respect
use
endow
phagebas
materi
similar
properti
fiberform
platform
discuss
filament
phage
highli
engineer
coat
protein
allow
high
densiti
surfac
display
select
protein
phage
natur
filament
resembl
peptid
peptideamphiphil
nanofib
morpholog
less
nm
diamet
yet
almost
length
bacteriophag
unabl
infect
mammalian
cell
neglig
risk
virul
infect
use
virus
medic
applic
reason
histor
use
antimicrobi
agent
current
approv
use
food
product
seen
limit
use
clinic
trial
therapeut
exampl
exist
tissuetarget
tumorhom
abil
full
phage
librari
test
human
bacteriophag
initi
investig
nanomateri
observ
form
liquid
crystal
prove
use
templat
inorgan
structur
incorpor
metal
bind
peptid
viral
coat
protein
follow
discoveri
function
liquid
crystallin
behavior
util
form
align
matric
neural
cell
cultur
display
argglyasp
rgd
ilelysvalalav
ikvav
peptid
phage
surfac
work
includ
use
standard
phage
display
select
optim
acid
sequenc
receptor
bind
result
filament
phage
produc
e
coli
rel
simpl
manufactur
process
like
scalabl
anoth
recent
exampl
preclin
materi
develop
use
filament
phage
selftempl
properti
prove
use
control
direct
osteoblast
growth
use
orient
phagebas
substrat
use
selftempl
fabric
direction
phage
substrat
allow
direct
growth
human
fibroblast
prolifer
elong
neural
progenitor
cell
stimul
differenti
mesenchym
stem
cell
osteoblast
phage
display
osteogen
peptid
surfac
vivo
inject
materi
phage
use
preclin
carrier
magnet
nanoparticl
target
imag
cancer
tumor
display
high
densiti
target
ligand
metal
bind
peptid
phage
surfac
relat
studi
use
modifi
approach
conjug
streptavidinlink
fluorophor
phage
display
tumortarget
streptavidinbind
peptid
surfac
target
cancer
imag
without
use
metal
particl
studi
demonstr
import
direct
pattern
combin
display
specif
peptid
phage
moreov
incorpor
multipl
bioactiv
phage
popul
singl
materi
requir
adjust
mixtur
variou
deposit
phage
way
materi
featur
modular
characterist
supramolecular
system
similar
nanofibr
materi
filament
phage
materi
receiv
signific
attent
induc
osteogenesi
form
collagenmimet
bundl
miner
hydroxyapatit
similarli
pa
peptid
nanofib
display
anioin
peptid
caus
parallel
assembl
individu
phage
presenc
cation
follow
format
orient
crystal
counterion
introduc
owe
local
supersatur
inorgan
ion
approach
close
resembl
demonstr
pa
miner
present
stupp
cowork
illustr
conserv
biolog
process
across
materi
platform
sinc
demonstr
phage
assembl
miner
osteogenesi
studi
expand
includ
present
hydroxyapatit
nucleat
protein
dentin
matrix
altern
moieti
induc
crystal
format
tobacco
mosiac
viru
tmv
anoth
rodlik
viru
shown
caus
differenti
mesenchym
stem
cell
bone
cell
cultur
tmv
coat
substrat
caus
upregul
osteocalcin
calcium
sequestr
marker
bone
develop
recent
rgdbear
phage
ceram
scaffold
induc
osteogenesi
angiogenesi
concurr
without
addit
exogen
vascular
endotheli
growth
factor
scale
phage
produc
may
manufactur
advantag
design
materi
past
year
supramolecular
assembl
peptid
protein
develop
singl
vaccin
broad
rang
technolog
span
breadth
biomateri
applic
drug
deliveri
vehicl
scaffold
tissu
regener
therapeut
current
sever
achiev
regulatori
approv
clinic
use
tabl
primarili
vaccin
space
advanc
platform
attribut
mani
factor
peptid
protein
econom
ever
produc
manufactur
effici
continu
develop
design
rule
subclass
materi
significantli
map
recent
year
strategi
optim
incorpor
diseasespecif
ligand
epitop
moieti
within
platform
expect
come
decad
wit
implement
mani
new
exampl
supramolecular
polypeptid
therapi
immunogen
featur
peptid
assembl
advantag
develop
synthet
vaccin
engin
immunotherapi
topic
recent
review
group
other
also
import
note
assembl
contain
high
densiti
protein
peptid
ligandsepitop
multival
display
may
induc
unwant
immun
respons
remain
seen
whether
respons
toler
specif
applic
could
even
turn
favor
materi
clinic
perform
interestingli
neither
curodont
purastat
contain
specif
ligandsepitop
possibl
avoid
immunogen
may
observ
trial
nanofibr
materi
contain
addit
protein
peptid
function
compon
addit
futur
work
may
focu
investig
biodistribut
pharmacokinet
preclin
selfassembl
materi
due
dynam
natur
materi
import
understand
vivo
environ
affect
longterm
structur
organ
retent
clearanc
order
clinic
translat
platform
must
also
capabl
largescal
product
stabl
storag
unlik
tradit
small
molecul
materi
must
gener
kept
monomer
otherwis
stabl
state
assembl
prior
administr
issu
repres
import
consider
yet
fulli
work
supramolecular
materi
sever
selfassembl
platform
discov
develop
past
year
worth
consid
crossroad
lay
ahead
focu
develop
promis
platform
discuss
continu
search
new
novel
platform
one
hand
sever
aforement
platform
shown
encourag
preclin
data
investig
new
diseas
model
discoveri
new
efficaci
versatil
platform
could
spur
unforeseen
therapi
base
selfassembl
concept
either
way
predict
selfassembl
peptid
protein
technolog
continu
make
stride
preclin
clinic
realm
